Stefania Gori

9.5k total citations
180 papers, 3.5k citations indexed

About

Stefania Gori is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Stefania Gori has authored 180 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 48 papers in Cancer Research. Recurrent topics in Stefania Gori's work include Breast Cancer Treatment Studies (36 papers), HER2/EGFR in Cancer Research (30 papers) and Cancer Treatment and Pharmacology (29 papers). Stefania Gori is often cited by papers focused on Breast Cancer Treatment Studies (36 papers), HER2/EGFR in Cancer Research (30 papers) and Cancer Treatment and Pharmacology (29 papers). Stefania Gori collaborates with scholars based in Italy, United States and United Kingdom. Stefania Gori's co-authors include Alessandro Inno, Lucio Crinò, Mariantonietta Colozza, Angelo Sidoni, Antonio Russo, Lucia Del Mastro, Giulio Metro, Vienna Ludovini, Verena De Angelis and Teresa Gamucci and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stefania Gori

170 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefania Gori Italy 30 2.0k 897 694 680 507 180 3.5k
Sercan Aksoy Türkiye 27 1.7k 0.9× 780 0.9× 430 0.6× 554 0.8× 403 0.8× 284 3.6k
Nicolaì Maass Germany 33 1.8k 0.9× 773 0.9× 1.1k 1.6× 1.3k 2.0× 399 0.8× 274 4.9k
Cinzia Orlandini Italy 29 2.2k 1.1× 877 1.0× 630 0.9× 622 0.9× 267 0.5× 74 3.7k
Flora Zagouri Greece 33 1.7k 0.9× 718 0.8× 873 1.3× 1.2k 1.7× 227 0.4× 301 4.0k
Lukas Hefler Austria 42 1.5k 0.8× 460 0.5× 774 1.1× 1.2k 1.7× 406 0.8× 208 5.1k
Ondřej Topolčan Czechia 31 1.6k 0.8× 1.0k 1.2× 1.1k 1.5× 1.3k 1.9× 176 0.3× 254 4.2k
Eliana Rulli Italy 33 2.6k 1.3× 1.3k 1.5× 687 1.0× 1.1k 1.5× 157 0.3× 130 4.4k
Masashi Ando Japan 31 2.0k 1.0× 954 1.1× 774 1.1× 688 1.0× 203 0.4× 206 3.6k
K. Höffken Germany 36 2.6k 1.3× 848 0.9× 540 0.8× 1.1k 1.7× 424 0.8× 186 5.4k
Federica Tomao Italy 38 2.0k 1.0× 1.0k 1.1× 731 1.1× 1.2k 1.7× 194 0.4× 243 4.9k

Countries citing papers authored by Stefania Gori

Since Specialization
Citations

This map shows the geographic impact of Stefania Gori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefania Gori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefania Gori more than expected).

Fields of papers citing papers by Stefania Gori

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefania Gori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefania Gori. The network helps show where Stefania Gori may publish in the future.

Co-authorship network of co-authors of Stefania Gori

This figure shows the co-authorship network connecting the top 25 collaborators of Stefania Gori. A scholar is included among the top collaborators of Stefania Gori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefania Gori. Stefania Gori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gallucci, Giuseppina, Alessandro Navazio, Fabio Maria Turazza, et al.. (2025). Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management. International Journal of Molecular Sciences. 26(1). 334–334. 3 indexed citations
2.
Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2025). Prognostic implications of risk definitions from the monarchE and NATALEE trials. JNCI Journal of the National Cancer Institute. 117(6). 1198–1208. 3 indexed citations
3.
Mennini, Francesco Saverio, Andrea Marcellusi, Paolo Sciattella, et al.. (2024). Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis. PharmacoEconomics - Open. 9(2). 283–290.
4.
Franceschini, Gianluca, Camilla Nero, Ida Paris, et al.. (2024). Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital. Journal of Personalized Medicine. 14(4). 371–371.
5.
Gori, Stefania, Alberto Zambelli, Catia Angiolini, et al.. (2024). Follow-up of breast cancer: why is it necessary to start a Consensus in 2024?. SHILAP Revista de lepidopterología. 11(1). 10–17.
6.
Foti, Giovanni, Giorgio Ascenti, Andrea Agostini, et al.. (2024). Dual-Energy CT in Oncologic Imaging. Tomography. 10(3). 299–319. 9 indexed citations
7.
Inno, Alessandro, Giuseppe Bogina, Matteo Salgarello, et al.. (2023). First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression. SHILAP Revista de lepidopterología. 17. 110–113. 3 indexed citations
8.
Inno, Alessandro, et al.. (2023). Mucoepidermoid Carcinoma of the Lung Harboring MET Exon 14 Skipping Mutation Treated With Tepotinib: A Case Report. JCO Precision Oncology. 7(7). e2300136–e2300136.
9.
Muscaritoli, Maurizio, Alessandra Modena, Paolo Marchetti, et al.. (2023). The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study. Cancers. 15(12). 3206–3206. 9 indexed citations
10.
Ceccaroni, Marcello, Giovanni Roviglione, Francesco Bruni, et al.. (2023). “Things Have Changed”—Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients. Cancers. 15(24). 5726–5726.
11.
Miglietta, Federica, Michela Cinquini, Maria Vittoria Dieci, et al.. (2022). PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. The Breast. 66. 293–304. 7 indexed citations
12.
13.
Incorvaia, Lorena, Lidia Rita Corsini, Chiara Brando, et al.. (2021). Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. Critical Reviews in Oncology/Hematology. 163. 103390–103390. 5 indexed citations
14.
Cagnazzo, Celeste, Alessandro Costanzo, Stefania Gori, et al.. (2020). Patient associations and clinical oncology research: how much does a patient’s voice really matter?. Expert Review of Pharmacoeconomics & Outcomes Research. 21(3). 433–440. 2 indexed citations
15.
Petrelli, Fausto, Alessandro Iaculli, Diego Signorelli, et al.. (2020). Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. Preprints.org. 11 indexed citations
16.
17.
Salgarello, Matteo, et al.. (2016). 18F-NaF PET/CT Imaging of Brain Metastases. Clinical Nuclear Medicine. 41(7). 564–565. 15 indexed citations
18.
Mandarano, Martina, Biagio Ricciuti, Rita Chiari, et al.. (2016). Müllerian Tumor Originating from the Pleura in a 47-Years Old Woman: A Case Report. 1(1). 1 indexed citations
19.
Tarantini, Luigi, Pompilio Faggiano, Sandro Barni, & Stefania Gori. (2013). Monitoraggio del danno cardiaco nel paziente oncologico in trattamento con farmaci cardiotossici. Giornale italiano di cardiologia. 14(6). 416–23. 1 indexed citations
20.
Gori, Stefania, Matteo Clavarezza, Salvatore Siena, et al.. (2012). Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer. 12(1). 158–158. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sercan Aksoy Breakdown of academic impact, for papers by Nicolaì Maass Breakdown of academic impact, for papers by Cinzia Orlandini Breakdown of academic impact, for papers by Flora Zagouri Breakdown of academic impact, for papers by Lukas Hefler Breakdown of academic impact, for papers by Ondřej Topolčan Breakdown of academic impact, for papers by Eliana Rulli Breakdown of academic impact, for papers by Masashi Ando Breakdown of academic impact, for papers by K. Höffken Breakdown of academic impact, for papers by Federica Tomao
Rankless by CCL
2026